RHHBF
Roche Holding AG
Set alert
501.04 USD +11.04 +2.25%
500.01 Day range 500.01
316.30 52-week range 501.04
- YTD
- +12.44%
- 1 year
- +43.15%
- Open
- 500.01
- Prev close
- 490.00
- Mkt cap
- 399.21B
- Vol
- 2
- Avg vol
- 95
- EPS
- 19.32
- P/E
- 25.93
More statistics
- Low
- 500.01
- High
- 500.01
- Earnings
- Jul 23, 2026
Next earnings
Jul 23, 2026
Expected Jul 23, 2026. Consensus EPS estimate 12.51.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | — | — | — |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 5.81 | -7.37 | -55.92% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 2.77 | -6.48 | -70.05% |
| Oct 23, 2024 | Jun 30, 2024 | 10.42 | 8.71 | -1.71 | -16.41% |
| Apr 26, 2024 | Dec 31, 2023 | 10.07 | 6.34 | -3.73 | -37.04% |
News
- Roche: Valuation Leaves Limited Upside
- Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
- Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
- Roche says divarasib cut risk of death 44% in lung cancer trial
- Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
- Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
- Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
- Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
- Roche Holding AG (RHHBY) Q3 2026 Sales/Trading Call Transcript
- Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Your note
Sign in to keep a note on RHHBF — it syncs with the Stock Master app.